This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
An important prerequisite for an inflammatory response to occur is the trafficking of blood-borne leukocytes from the blood to the site of inflammation. This process has been studied extensively, and many of the molecules responsible for leukocyte adhesion and concurrent extravasation have been elucidated (reviewed in ref. 1).
Leukocyte extravasation can be divided into three distinct stages(figure). The first stage, termed tethering and/or rolling, is mediated by a family of adhesion molecules called selectins. Selectins consist of three structurally homologous proteins that are expressed on leukocytes (L-selectin), platelets (P-selectin), and endothelial cells (E-selectin and P-selectin). In this first stage, a leukocyte that is flowing freely in the blood makes the initial contact with the inflamed vasculature at or near the site of the trauma and then rolls to a site close to where the leukocyte will ultimately leave the bloodstream in its journey to the lesion.
Figure. Depiction of a granulocyte going through the three stages of extravasation to traffic to an inflammatory lesion. The first stage is selectin-mediated rolling. The second, "adhesion strengthening stage," is mediated by the CD18 members LFA-1 and MAC-1 interacting with ICAM-1 and ICAM-2. The …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker